论文部分内容阅读
目的观察顺铂与足叶乙甙联合体部γ-刀同步治疗局限期小细胞肺癌的临床疗效。方法局限期小细胞肺癌患者68例,采用信封抽签随机分为同步治疗组(A组)和序贯治疗组(B组)。两组患者均接受顺铂与足叶乙甙化疗6周期和体部γ-刀治疗6~10次。A组患者化疗与γ-刀治疗同步进行;B组先给予4个周期的化疗,再进行γ-刀治疗,然后再化疗2个周期。结果A组患者的中位生存期24个月,3年生存率为32%;B组患者的中位生存期为16个月,3年生存率为18%,两组比较差异有显著性(P<0.05)。两组患者的主要毒副反应为骨髓抑制,Ⅲ、Ⅳ度的白细胞下降发生率A组为91.2%(31/34),B组为67.6%(23/34),两组比较差异有显著性(P<0.05)。结论顺铂与足叶乙甙方案联合体部γ-刀同步治疗局限期小细胞肺癌,能提高患者的生存期和生存率。
Objective To observe the clinical efficacy of cisplatin and etoposide in combination with gamma knife in the treatment of small cell lung cancer (NSCLC). Methods Sixty-eight patients with small-cell lung cancer (NSCLC) were enrolled in this study. They were randomized into two groups: group A (synchronous treatment) and group B (sequential treatment). Both groups received 6 cycles of cisplatin and etoposide and 6 to 10 cycles of gamma knife treatment. Group A patients with chemotherapy and γ-knife treatment simultaneously; Group B was given 4 cycles of chemotherapy, followed by γ-knife treatment, and then 2 cycles of chemotherapy. Results The median survival time in group A was 24 months and the 3-year survival rate was 32%. The median survival time in group B was 16 months and the 3-year survival rate was 18%. There was significant difference between the two groups P <0.05). The main adverse reaction was myelosuppression in both groups. The incidence of grade Ⅲ and Ⅳ leukopenia in group A was 91.2% (31/34) in group A and 67.6% (23/34) in group B, the difference was significant between the two groups (P <0.05). Conclusions Cisplatin and etoposide combined with γ-knife simultaneous treatment of localized small cell lung cancer can improve the survival and survival of patients.